ERLEADA Drug Patent Profile
✉ Email this page to a colleague
When do Erleada patents expire, and when can generic versions of Erleada launch?
Erleada is a drug marketed by Janssen Biotech and is included in one NDA. There are eleven patents protecting this drug and one Paragraph IV challenge.
This drug has two hundred and eighty-two patent family members in forty-six countries.
The generic ingredient in ERLEADA is apalutamide. One supplier is listed for this compound. Additional details are available on the apalutamide profile page.
DrugPatentWatch® Generic Entry Outlook for Erleada
Erleada was eligible for patent challenges on February 14, 2022.
By analyzing the patents and regulatory protections it appears that the earliest date
for generic entry will be June 4, 2033. This may change due to patent challenges or generic licensing.
There have been seven patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.
Indicators of Generic Entry
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ERLEADA?
- What are the global sales for ERLEADA?
- What is Average Wholesale Price for ERLEADA?
Summary for ERLEADA
| International Patents: | 282 |
| US Patents: | 11 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 84 |
| Clinical Trials: | 22 |
| Patent Applications: | 579 |
| Drug Prices: | Drug price information for ERLEADA |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for ERLEADA |
| What excipients (inactive ingredients) are in ERLEADA? | ERLEADA excipients list |
| DailyMed Link: | ERLEADA at DailyMed |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for ERLEADA
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Recent Clinical Trials for ERLEADA
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| University of Washington | Phase 2 |
| Jonsson Comprehensive Cancer Center | Phase 2 |
| National Cancer Institute (NCI) | Phase 1 |
Paragraph IV (Patent) Challenges for ERLEADA
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| ERLEADA | Tablets | apalutamide | 60 mg | 210951 | 5 | 2022-02-14 |
US Patents and Regulatory Information for ERLEADA
ERLEADA is protected by fifteen US patents.
Based on analysis by DrugPatentWatch, the earliest date for a generic version of ERLEADA is ⤷ Sign Up.
This potential generic entry date is based on patent ⤷ Sign Up.
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
Patents protecting ERLEADA
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT IN COMBINATION WITH A GNRH AGONIST OF HIGH RISK NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT IN COMBINATION WITH ANDROGEN DEPRIVATION THERAPY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) THAT IMPROVES METASTASIS FREE SURVIVAL
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT IN COMBINATION WITH ORCHIECTOMY OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC)
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION SENSITIVE PROSTATE CANCER
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
Substituted diazaspiroalkanes as androgen receptor modulators
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Crystalline forms of an androgen receptor modulator
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC)
Crystalline forms of an androgen receptor modulator
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Anti-androgens for the treatment of non-metastatic castrate-resistant prostate cancer
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
Substituted diazaspiroalkanes as androgen receptor modulators
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: TREATMENT IN COMBINATION WITH A GNRH AGONIST OF NON-METASTATIC, CASTRATION-RESISTANT PROSTATE CANCER (NM-CRPC)
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-001 | Feb 14, 2018 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | Y | ⤷ Sign Up | ||
| Janssen Biotech | ERLEADA | apalutamide | TABLET;ORAL | 210951-002 | Feb 17, 2023 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
EU/EMA Drug Approvals for ERLEADA
| Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
|---|---|---|---|---|---|---|---|---|---|
| Janssen-Cilag International NV | Erleada | apalutamide | EMEA/H/C/004452 Erleada is indicated:in adult men for the treatment of non metastatic castration resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease.in adult men for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) in combination with androgen deprivation therapy (ADT). |
Authorised | no | no | no | 2019-01-14 | |
| >Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for ERLEADA
When does loss-of-exclusivity occur for ERLEADA?
Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:
Australia
Patent: 13271751
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Patent: 17200298
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Patent: 17279807
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Brazil
Patent: 2014030678
Patent: formas cristalinas de um modulador de receptor de androgênio
Estimated Expiration: ⤷ Sign Up
Canada
Patent: 75767
Patent: FORMES CRISTALLINES D'UN MODULATEUR DU RECEPTEUR DES ANDROGENES (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 08345
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RECEPTEUR D'ANDROGENE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 55660
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RECEPTEUR D'ANDROGENE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 14726
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RECEPTEUR D'ANDROGENE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Chile
Patent: 14003331
Patent: Formas cristalinas de un modulador de receptor de androgeno
Estimated Expiration: ⤷ Sign Up
China
Patent: 4619692
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Patent: 5693692
Patent: 雄激素受体调节剂的晶形
Estimated Expiration: ⤷ Sign Up
Patent: 3135892
Patent: 雄激素受体调节剂的晶形 (Crystalline form of androgen receptor modulator)
Estimated Expiration: ⤷ Sign Up
Colombia
Patent: 40407
Patent: Formas cristalinas de un modulador del receptor androgénico
Estimated Expiration: ⤷ Sign Up
Costa Rica
Patent: 140549
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO
Estimated Expiration: ⤷ Sign Up
Patent: 190331
Patent: UNA FORMA CRISTALINA A DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO (Divisional 2014-0549) (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Croatia
Patent: 0180902
Estimated Expiration: ⤷ Sign Up
Patent: 0201387
Estimated Expiration: ⤷ Sign Up
Patent: 0210909
Estimated Expiration: ⤷ Sign Up
Cyprus
Patent: 20393
Estimated Expiration: ⤷ Sign Up
Patent: 23427
Estimated Expiration: ⤷ Sign Up
Patent: 24831
Estimated Expiration: ⤷ Sign Up
Denmark
Patent: 58985
Estimated Expiration: ⤷ Sign Up
Patent: 48553
Estimated Expiration: ⤷ Sign Up
Patent: 33792
Estimated Expiration: ⤷ Sign Up
Ecuador
Patent: 14030098
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO
Estimated Expiration: ⤷ Sign Up
Eurasian Patent Organization
Patent: 8791
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА МОДУЛЯТОРА АНДРОГЕННЫХ РЕЦЕПТОРОВ (CRYSTALLINE FORM OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 3956
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА А 4-[7-(6-ЦИАНО-5-ТРИФТОРМЕТИЛПИРИДИН-3-ИЛ)-8-ОКСО-6-ТИОКСО-5,7- ДИАЗАСПИРО[3.4]ОКТ-5-ИЛ]-2-ФТОР-N-МЕТИЛБЕНЗАМИДА ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ, СВЯЗАННОГО С АКТИВНОСТЬЮ АНДРОГЕННЫХ РЕЦЕПТОРОВ, ВКЛЮЧАЯ РАК ПРОСТАТЫ (CRYSTALLINE FORM OF 4-[7-(6-CYANO-5-TRIFLUOROMETHYLPYRIDIN-3-YL)-8-OXO-6-THIOXO-5,7-DIAZASPIRO[3.4]OCT-5-YL]-2-FLUORO-N-METHYLBENZAMIDE FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ANDROGEN RECEPTOR ACTIVITY, INCLUDING PROSTATE CANCER)
Estimated Expiration: ⤷ Sign Up
Patent: 1492272
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ МОДУЛЯТОРА АНДРОГЕННЫХ РЕЦЕПТОРОВ
Estimated Expiration: ⤷ Sign Up
Patent: 1791592
Patent: КРИСТАЛЛИЧЕСКИЕ ФОРМЫ МОДУЛЯТОРА АНДРОГЕННЫХ РЕЦЕПТОРОВ
Estimated Expiration: ⤷ Sign Up
Patent: 1992010
Patent: КРИСТАЛЛИЧЕСКАЯ ФОРМА А 4-[7-(6-ЦИАНО-5-ТРИФТОРМЕТИЛПИРИДИН-3-ИЛ)-8-ОКСО-6-ТИОКСО-5,7-ДИАЗАСПИРО[3.4]ОКТ-5-ИЛ]-2-ФТОР-N-МЕТИЛБЕНЗАМИДА ДЛЯ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЯ ИЛИ СОСТОЯНИЯ, СВЯЗАННОГО С АКТИВНОСТЬЮ АНДРОГЕННЫХ РЕЦЕПТОРОВ, ВКЛЮЧАЯ РАК ПРОСТАТЫ
Estimated Expiration: ⤷ Sign Up
European Patent Office
Patent: 58985
Patent: FORMES CRISTALLINES D'UN MODULATEUR DU RÉCEPTEUR DES ANDROGÈNES (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 48553
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RÉCEPTEUR D'ANDROGÈNE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 33792
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RÉCEPTEUR D'ANDROGÈNE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 22629
Patent: FORMES CRISTALLINES D'UN MODULATEUR DE RÉCEPTEUR D'ANDROGÈNE (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
France
Patent: C1050
Estimated Expiration: ⤷ Sign Up
Guatemala
Patent: 1400283
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGÉNICO
Estimated Expiration: ⤷ Sign Up
Hong Kong
Patent: 10175
Patent: 雄激素受體調節劑的晶形 (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 26066
Patent: 雄激素受體調節劑的晶形 (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Hungary
Patent: 38082
Estimated Expiration: ⤷ Sign Up
Patent: 50357
Estimated Expiration: ⤷ Sign Up
Patent: 54595
Estimated Expiration: ⤷ Sign Up
Patent: 100047
Estimated Expiration: ⤷ Sign Up
India
Patent: 084DEN2014
Estimated Expiration: ⤷ Sign Up
Israel
Patent: 9738
Patent: צורות גבישיות של מאפנן קולטן אנדרוגן (Crystalline forms of an androgen receptor modulator)
Estimated Expiration: ⤷ Sign Up
Patent: 7608
Patent: צורות גבישיות של מאפנן קולטן אנדרוגן (Crystalline forms of an androgen receptor modulator)
Estimated Expiration: ⤷ Sign Up
Patent: 5413
Patent: צורות גבישיות של מאפנן קולטן אנדרוגן (Crystalline forms of an androgen receptor modulator)
Estimated Expiration: ⤷ Sign Up
Japan
Patent: 82209
Estimated Expiration: ⤷ Sign Up
Patent: 45821
Estimated Expiration: ⤷ Sign Up
Patent: 15518890
Patent: アンドロゲン受容体変調剤の結晶質形態
Estimated Expiration: ⤷ Sign Up
Patent: 17178923
Patent: アンドロゲン受容体変調剤の結晶質形態 (CRYSTALLINE FORMS OF ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 18141009
Patent: アンドロゲン受容体変調剤の結晶質形態 (CRYSTALLINE FORMS OF ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Lithuania
Patent: 2021525
Estimated Expiration: ⤷ Sign Up
Patent: 58985
Estimated Expiration: ⤷ Sign Up
Patent: 48553
Estimated Expiration: ⤷ Sign Up
Patent: 33792
Estimated Expiration: ⤷ Sign Up
Malaysia
Patent: 7500
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Mexico
Patent: 6754
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGENICO. (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR.)
Estimated Expiration: ⤷ Sign Up
Patent: 14015005
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGENICO. (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR.)
Estimated Expiration: ⤷ Sign Up
Montenegro
Patent: 081
Patent: MODULATORA RECEPTORA ANDROGENA PATENTNI ZAHTEVI (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 815
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
New Zealand
Patent: 2203
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Patent: 7683
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Nicaragua
Patent: 1400142
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR DE ANDROGENOS
Estimated Expiration: ⤷ Sign Up
Norway
Patent: 21046
Estimated Expiration: ⤷ Sign Up
Peru
Patent: 150631
Patent: FORMAS CRISTALINAS DE UN MODULADOR DEL RECEPTOR ANDROGENICO
Estimated Expiration: ⤷ Sign Up
Patent: 200725
Patent: FORMAS CRISTALINAS DEL MODULADOR RECEPTOR DE ANDROGENO: 4-[7-(6-CIANO-5-TRIFLUOROMETILPIRIDIN-3-IL)-8-OXO-6-TIOXO-5,7-DIAZAESPIRO[3,4]OCT-5-IL]-2-FLUORO-N-METILBENZAMIDA) (APALUTAMIDA)
Estimated Expiration: ⤷ Sign Up
Philippines
Patent: 014502714
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Patent: 016501470
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Poland
Patent: 58985
Estimated Expiration: ⤷ Sign Up
Patent: 48553
Estimated Expiration: ⤷ Sign Up
Patent: 33792
Estimated Expiration: ⤷ Sign Up
Portugal
Patent: 58985
Estimated Expiration: ⤷ Sign Up
Patent: 48553
Estimated Expiration: ⤷ Sign Up
Patent: 33792
Estimated Expiration: ⤷ Sign Up
Serbia
Patent: 370
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 617
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 988
Patent: KRISTALNI OBLICI MODULATORA RECEPTORA ANDROGENA (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Singapore
Patent: 201610248S
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Patent: 201610249T
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Patent: 201408140Q
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Slovenia
Patent: 58985
Estimated Expiration: ⤷ Sign Up
Patent: 48553
Estimated Expiration: ⤷ Sign Up
Patent: 33792
Estimated Expiration: ⤷ Sign Up
South Africa
Patent: 1500076
Patent: CRYSTALLINE FORMS OF ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
South Korea
Patent: 2062024
Estimated Expiration: ⤷ Sign Up
Patent: 2195916
Estimated Expiration: ⤷ Sign Up
Patent: 150021993
Patent: CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR
Estimated Expiration: ⤷ Sign Up
Patent: 190132543
Patent: 안드로겐 수용체 조절제의 결정 형태 (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Spain
Patent: 70683
Estimated Expiration: ⤷ Sign Up
Patent: 09738
Estimated Expiration: ⤷ Sign Up
Patent: 75932
Estimated Expiration: ⤷ Sign Up
Taiwan
Patent: 32732
Estimated Expiration: ⤷ Sign Up
Patent: 1402561
Patent: Crystalline forms of an androgen receptor modulator
Estimated Expiration: ⤷ Sign Up
Turkey
Patent: 1808939
Estimated Expiration: ⤷ Sign Up
Ukraine
Patent: 5665
Patent: КРИСТАЛІЧНІ ФОРМИ МОДУЛЯТОРА АНДРОГЕННОГО РЕЦЕПТОРА (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR)
Estimated Expiration: ⤷ Sign Up
Patent: 3142
Patent: КРИСТАЛІЧНІ ФОРМИ МОДУЛЯТОРА АНДРОГЕННОГО РЕЦЕПТОРА
Estimated Expiration: ⤷ Sign Up
Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.
See the table below for additional patents covering ERLEADA around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| European Patent Office | 2858985 | FORMES CRISTALLINES D'UN MODULATEUR DU RÉCEPTEUR DES ANDROGÈNES (CRYSTALLINE FORMS OF AN ANDROGEN RECEPTOR MODULATOR) | ⤷ Sign Up |
| Cyprus | 1118026 | ⤷ Sign Up | |
| Slovenia | 3348553 | ⤷ Sign Up | |
| Denmark | 3412290 | ⤷ Sign Up | |
| Japan | 2019163288 | 非転移性去勢抵抗性前立腺癌の治療のための抗アンドロゲン剤 (ANTI-ANDROGENS FOR THE TREATMENT OF NON-METASTATIC, CASTRATE-RESISTANT PROSTATE CANCER) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for ERLEADA
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2368550 | 1990032-3 | Sweden | ⤷ Sign Up | PRODUCT NAME: APALUTAMIDE; REG. NO/DATE: EU/1/1342 20190116 |
| 3533792 | 122021000067 | Germany | ⤷ Sign Up | PRODUCT NAME: APALUTAMID; REGISTRATION NO/DATE: EU/1/18/1342 20190114 |
| 2368550 | LUC00123 | Luxembourg | ⤷ Sign Up | PRODUCT NAME: APALUTAMIDE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/18/1342 20190116 |
| 3533792 | 43/2021 | Austria | ⤷ Sign Up | PRODUCT NAME: APALUTAMID; REGISTRATION NO/DATE: EU/1/18/1342 (MITTEILUNG) 20190116 |
| 2368550 | 300993 | Netherlands | ⤷ Sign Up | PRODUCT NAME: APALUTAMIDE OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/18/1342 20190116 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
